StockData

MediciNova vs 60 Degrees Pharmaceuticals

MNOV and SXTP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MNOV and SXTP compare

MediciNova is the larger company, worth 35 times as much as 60 Degrees Pharmaceuticals ($66.0M against $1.9M).

60 Degrees Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −730% compared with −1168% at MediciNova.

60 Degrees Pharmaceuticals scores higher on the StockData Score (8 against 7 for MediciNova), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMNOVSXTP
Size and price
Market cap$66.0M$1.9M
Share price$1.34$0.534
Change, 1 year−13.5%−85.3%
Change, 5 years−58.4%–
Beta (5Y)−0.001.92
Employees63
StockData Score
Total score78 (better)
Valuation score13 (better)
Growth score02 (better)
Performance score11
Health score5 (better)2
Dividend score00
Valuation
P/S71.7×1.7× (better)
P/B1.8×0.7× (better)
FCF yield−13.8% (better)−474%
Fair value–$1.34
Margin of safety–60.2%
Growth
Revenue growth (TTM)–73.2%
Profitability
Gross margin–19.4%
Operating margin−1287%−775% (better)
Net margin−1168%−730% (better)
FCF margin−991%−801% (better)
Return on equity−25.6% (better)−322%
Return on invested capital−76.6% (better)−659%
Financial health
Debt / equity0.000.00 (better)
Interest coverage–−1134.8×
Current ratio8.75 (better)2.32
Altman Z-score−3.11 (better)−22.22
Piotroski F-score22
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions10.5%21.5%
Held by insiders12.8%21.0%
Insider net buying, 12 months−$1.7M$30.1K (better)
Short interest, % of float0.66%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.